© 2018

Innovations for Next-Generation Antibody-Drug Conjugates

  • Marc Damelin

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Philipp Müller, Jonathan Rios-Doria, Jay Harper, Anthony Cao
    Pages 11-44
  3. Magali Guffroy, Hadi Falahatpisheh, Martin Finkelstein
    Pages 45-71
  4. Elizabeth VanAlphen, Omar Perez
    Pages 99-111
  5. L. Nathan Tumey
    Pages 187-214
  6. Natalya Bodyak, Alexander V. Yurkovetskiy
    Pages 215-240
  7. Feng Tian, Dowdy Jackson, Yun Bai
    Pages 241-265
  8. Frank Comer, Changshou Gao, Steve Coats
    Pages 267-280
  9. Alberto Dal Corso, Samuele Cazzamalli, Dario Neri
    Pages 299-319
  10. Shan Yu, Andrew Lim, Matthew S. Tremblay
    Pages 321-347
  11. Back Matter
    Pages 349-357

About this book


Antibody-drug conjugates (ADCs) stand at the verge of a transformation.  Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges.  This volume focuses on the next generation of ADCs and the innovations that will enable them.  The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies.  While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.

The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.  However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing.  The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies.  These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.


Antibody-Drug Conjugates pharmacokinetics, oncology immuno-oncology Conjugation

Editors and affiliations

  • Marc Damelin
    • 1
  1. 1.Mersana Therapeutics, Inc.CambridgeUSA

About the editors

Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation. 

Bibliographic information

  • Book Title Innovations for Next-Generation Antibody-Drug Conjugates
  • Editors Marc Damelin
  • Series Title Cancer Drug Discovery and Development
  • Series Abbreviated Title Cancer Drug Discovery,Development
  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-3-319-78153-2
  • Softcover ISBN 978-3-030-08627-5
  • eBook ISBN 978-3-319-78154-9
  • Series ISSN 2196-9906
  • Series E-ISSN 2196-9914
  • Edition Number 1
  • Number of Pages VIII, 357
  • Number of Illustrations 18 b/w illustrations, 52 illustrations in colour
  • Topics Cancer Research
    Molecular Medicine
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods